Ruxolitinib May Be Effective for Reducing Spleen Length in Patients With Myelofibrosis
By week 24 of the study, a reduction in palpable spleen length of at least 50% was reported in more than half of patients who underwent splenomegaly.
All articles by Jonathan Goodman, MPhil
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Low-Dose Direct-Acting Oral Anticoagulants Cost-Effective for Thrombosis Prevention in Cancer
Thromboprophylaxis with a low-dose direct-acting oral anticoagulant was associated with lower incidences of cancer-associated thrombosis and bleeding compared with placebo.
Acquired TTP and Septic Disseminated Intravascular Coagulation Distinguishable With Lab Tests
Severe thrombocytopenia, antithrombin levels, and degree of fibrinogen degradation product elevation were found to be distinguishing factors of aTTP.
Total Therapy Approach May Improve Transplant Outcomes in Patients With Myeloma
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
Health and Psychological Well-Being in Patients With Hemophilia
Patients with hemophilia were found to experience worse general health but higher levels of psychological well-being compared with individuals in the control arm.
Emotional, Cognitive Issues Common in Pediatric Patients With Immune Thrombocytopenia
Fatigue, emotional and behavioral symptoms, and executive functioning were found to be associated with quality of life but not with bleeding severity and platelet count.
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Clonal Mutations in Donors May Show Expansion in Recipients After HSCT
Of clonal mutations found in donors, 84.2% were predicted to be molecularly pathogenic and 100% engrafted in recipients.
Next post in General Hematology
